Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tramadol hydrochloride + acetaminophen is a fixed-dose oral combination of two analgesics used for the short-term management (up to 5 days) of acute pain severe enough to require an opioid and when alternative treatments are inadequate. Tramadol is a centrally acting synthetic opioid analgesic that relieves pain primarily by binding to µ-opioid receptor and weakly inhibiting the reuptake of norepinephrine and serotonin in the central nervous system. Acetaminophen is a non-opioid analgesic and antipyretic that reduces pain and fever through inhibition of prostaglandin synthesis in the central nervous system. The combination provides better pain relief than either drug alone at lower doses. Tramadol carries risks typical of opioids including dependence and abuse potential; acetaminophen overdose can cause severe hepatotoxicity. This product is available only under restricted distribution programs due to its risk profile[1][3][4][5][8]. **Developers**: Janssen
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tramadol hydrochloride + acetaminophen.